Cygnus Technologies, LLC
Tammie Crabtree is a seasoned professional with extensive experience in biotechnology and customer service management. Currently serving as the Customer Service Manager and Lab Production Manager at Cygnus Technologies, LLC since October 2017, Tammie has a robust background that includes a position as Senior Laboratory Manager at AI BioTech from November 2009 to March 2016, where responsibilities included designing and synthesizing peptide products and developing solutions for technical challenges. Prior experience as Senior Laboratory Manager at Commonwealth Biotechnologies, Inc. from November 1998 to November 2009 involved managing projects in biomedical engineering, particularly in bone and tissue regeneration, biodefense, and Alzheimer's research, along with synthesizing peptides using both automated and manual techniques. Tammie holds a Bachelor of Science in Biology, Biotechnology, and Microbiology from East Carolina University, earned between 1995 and 1997.
This person is not in any teams
Cygnus Technologies, LLC
Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. Cygnus provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes. Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus also offers a unique approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits. Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems. Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process. Located in Southport, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.